Skip to main content
Mijn bibliotheek
Shop
Nieuws Boeken Tijdschriften E-learning Web-tv Video Audio
Tips voor Mijn BSL
UITGEBREID ZOEKEN
Inloggen
Top
Gepubliceerd in:
Oorzaken van hersenbeschadiging hoofdstuk lezen eerste hoofdstuk lezen

2018 | OriginalPaper | Hoofdstuk

17. Neuropsychologische aspecten van neurodegeneratieve aandoeningen

Auteur : Dr. Ben van Cranenburgh

Gepubliceerd in: Neuropsychologie

Uitgeverij: Bohn Stafleu van Loghum

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail
    Link delen
publish
Publiceer nu

Samenvatting

Neurodegeneratieve aandoeningen zijn doorgaans ongeneeslijke progressieve verzwakkende aandoeningen, op basis van degeneratie of verlies van neuronen of neuronennetwerken. Ze kunnen zich uiten in toenemende motorische, cognitieve, mentale en/of gedragsmatige stoornissen. De meeste neurodegeneratieve aandoeningen hebben een opvallend kernsymptoom, bijvoorbeeld cognitieve achteruitgang bij dementie, spierzwakte bij ALS, rigiditeit en tremor bij de ziekte van Parkinson. Bij vrijwel alle neurodegeneratieve aandoeningen kunnen ook neuropsychologische stoornissen bestaan, enerzijds als subtiel beginsymptoom, anderzijds in het kader van de zich verder ontwikkelende ziekte. Dit hoofdstuk bespreekt van de belangrijkste neurodegeneratieve aandoeningen de diagnostische criteria, de belangrijkste symptomen en verloop, met een accent op de neuropsychologische stoornissen: de dementieën, Parkinson-spectrum-aandoeningen, progressieve supranucleaire parese (PSP), corticobasale degeneratie (CBD), multisysteematrofie (MSA), ziekte van Huntington, multiple sclerose (MS), spinocerebellaire degeneraties, cerebrale amyloïde angiopathieën (CAA) en amyotrofische laterale sclerose (ALS). Het betreft hier een bondig overzicht. Voor uitgebreide informatie wordt verwezen naar tekstboeken klinische neurologie.
vorige hoofdstuk Neuropsychologie van de veroudering
Bijlagen
Alleen toegankelijk voor geautoriseerde gebruikers
Literatuur
1.
Garenfeld W, Piere MAGB van. Psychiatrie, somatische aandoeningen, somatisch-symptoomstoornis en verwante stoornissen. In: Clijsen M, Garenfeld W, Kuipers G, et al, redactie. Leerboek psychiatrie voor verpleegkundigen. Amsterdam: Reed Business Education; 2015. pag. 305–28.CrossRef
2.
APA. Diagnostic and Statistical Manual of mental disorders. 4th edition, text revised. Washington DC: American Psychiatric Association; 2000.
3.
Verdonschot T, Kat M. Neurocognitieve stoornissen. In: Clijsen M, Garenfeld W, Kuipers G, et al., redactie. Leerboek psychiatrie voor verpleegkundigen. Amsterdam: Reed Business Education; 2015. pag. 275–304.
4.
Stapert S, Diesfeldt H. Ouderen. In: Hendriks M, Kessels R, Gorissen M, et al., redactie. Neuropsychologische diagnostiek. Amsterdam: Boom; 2014. pag. 332–46.
5.
Jost BC, Grossberg GT. The evolution of psychiatric symptoms in alzheimer’s disease: a natural history study. J Am Geriatr Soc. 1996;44(9):1078–81.PubMedCrossRef
6.
Csukly G, Siraly E, Fodor Z, et al. The differentiation of amnestic type MCI from the non-amnestic types by structural MRI. Front Ag Neurosci. 2016;8/52:1–10.
7.
Petersen RC, Smith G, Ivnik R, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56:303–8.PubMedCrossRef
8.
Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Ageing-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement J Alzheimers Assoc. 2011;7(3):270–9.CrossRef
9.
Lyketsos CG, Carrillo MC, Ryan JM, et al. Neuropsychiatric symptoms in Alzheimer’s disease. Alzheimers Dement. 2011;7(5):532–9.CrossRef
10.
Peters ME, Rosenberg PB, Steinberg M, et al. Prevalence of neuropsychiatric symptoms in CIND and its subtypes: the Cache County Study. Am J Geriatr Psychiatry. 2012;20:416–24.PubMedPubMedCentralCrossRef
11.
Feil N. Validation: een nieuwe benadering in de omgang met demente bejaarden. Almere: Versluys; 1989.
12.
Flier W van der, Vugt M de. De ziekte van Alzheimer. In: Kessels R, Eling P, Ponds R, et al., redactie. Klinische neuropsychologie. Amsterdam: Boom; 2012. pag. 423–56.
13.
NVKG. Richtlijn Diagnostiek en Behandeling van Dementie. Utrecht: Nederlandse Vereniging voor Klinische Geriatrie; 2014.
14.
Dautzenberg PLJ, Schmand B, Vriens MTS, et al. De validiteit van de cognitieve screening-test en de ‘mini-mental state examination’ bij een groep oudere ziekenhuispatiënten. Ned Tijdschr Geneeskd. 1991;135:850–5.
15.
Deelman BG, Maring W, Otten V. De CST: een gestandaardiseerde screeningsmethode voor dementie. In: Schroots JJF, et al., redactie. Cognitieve screenings test. Lisse: Swets Zeitlinger; 1991. pag. 163–70.
16.
Ponds RWHM, Verhey FRJ, Rozendaal N, et al. Dementiescreening:validiteit van de Cognitieve Screeningstest (CST) en de Mini Mental State Examinatuon (MMSE). Tijdschr Gerontol Geriatr. 1992;23:94–9.
17.
Diesfeldt HFA. Betekenisanalyse van de cognitieve screening test (CST14). Tijdschr Gerontol Geriatr. 1996;27:215–20.PubMed
18.
Folstein MF, Folstein SE, McHugh PR. Mini mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiat Res. 1975;12:189–98.PubMedCrossRef
19.
Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr So. 2005;53(4):695–99. www.​mocatest.​org.PubMedCrossRef
20.
Thissen AJ, Bergen van F, Jonghe JF de, et al. Applicability and validity of the Dutch version of the Montreal Cognitive Assessment (MoCA-d) in diagnosing MCI. Tijdschr Gerontol Geriatr. 2010;41(6):231–40.
21.
Wattel L, Achterberg W, redactie. UNO-COG Toolkit – cognitieve meetinstrumenten voor de ouderenzorg- een practice based benadering. Amsterdam: Universitair netwerk ouderenzorg UNO-VUmc; 2010.
22.
Katz S, Ford AB, Moskowitz RW, et al. Studies of illness in the aged. The index of ADL: A standardized measure of biological and psychosocial function. JAMA 1963;185(12):914–9.PubMedCrossRef
23.
Lawton MP, Brody EM. Assessment of older people: Self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9(3):179–86.PubMedCrossRef
24.
Verstraten PF, Eekelen CWJ. Gedragsobservatieschaal voor de intramurale psychogeriatrie (GIP). Deventer: Van Loghum Slaterus; 1987.
25.
Verstraten PF. De GIP: veertien observatieschalen voor psychogeriatrische gedragsproblemen. Tijdschr Gerontol Geriatr. 1988;19(4):147–51.PubMed
26.
Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308–14.PubMedCrossRef
27.
Kat MG, Jonghe JF de, Aalten P, et al. Neuropsychiatrische symptomen bij dementie: psychometrische aspecten van de Nederlandse Neuropsychiatric Inventory (NPI). Tijdschr Gerontol Geriatrie. 2002;33:150–5.
28.
Kaufer D, Cummings JL. NPI-Q. J Clin Neurosci. 2000;12:233–9. (Nederlandse vertaling Jonghe JFM de, Kat MG, Kalisvaart CJ. 2003).
29.
Jonghe JF de, Kat MG, Reus R de. De validiteit van de gedragsobservatieschaal voor intramurale psychogeriatrie (GIP): een vergelijking met de Bop en NOSIE-30 in een psychiatrische observatiekliniek voor ouderen. Tijdschr Gerontol Geriatr. 1994;25:110–6.
30.
Jonghe JF de, Ooms ME, Ribbe MW. Verkorte gedragsobservatieschaal voor de intramurale psychogeriatrie (GIP-28). Tijdschr Gerontol Geriatr. 1997;28:119–23.
31.
Brodaty H, Green A, Koschera A. Meta-analysis of psychosocial interventions for caregivers of people with dementia. J Am Geriatr Soc. 2003;51:657–64.PubMedCrossRef
32.
Pot AM, Dyck R van, Deeg DJH. Ervaren druk door informele zorg; constructie van een schaal. Tijdschrift Gerontol Geriatr. 1995;26:214–9.
33.
Duijnstee M, Guldemond H, Hendriks L. Zorgkompas voor mantelzorgers van ouderen en chronisch zieken: leidraad voor het in kaart brengen van de belasting van zorgende familieleden. Utrecht: NIZW; 2001.
34.
APA. Diagnostic and Statistical Manual of mental disorders. 5th edition. Arlington, VA: American Psychiatric Association; 2013.
35.
36.
Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011;(134):2456–77.
37.
38.
Raaphorst J, Grupstra HF, Linssen WHJP, et al. Amyotrofische laterale sclerose en frontotemporale dementie. Ned Tijdschr Geneeskd. 2010;154/A631:1–6.
39.
Koning I de, Seelaar H. Frontotemporale dementie. In: Kessels R, Eling P, Ponds R, et al. Klinische neuropsychologie. Amsterdam: Boom; 2012. pag. 443–56.
40.
MacKenzie IRA, Neumann M, Bigio EH, et al. Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol. 2010;119:1–4.PubMedPubMedCentralCrossRef
41.
Snowden J., Neary D, Mann D. Frontotemporal lobar degeneration: frontotemporal dementia, progressive aphasia, semantic dementia. New York: Churchill Livingstone; 1996.
42.
Kertesz A, Davidson W, Fox H. Frontal Behavioral Inventory: Diagnostic Criteria for Frontal Lobe Dementia. Can J Neurol Sci. 1997;24:29–36.PubMedCrossRef
43.
Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: a Frontal Assessment Battery at bedside. Neurology. 2000;55:1621–6.PubMedCrossRef
44.
Loo EH van, Wiebrands C, Laar T van. De ‘Frontal Assessment Battery’ (FAB) voor screening op frontaalkwabpathologie bij neurodegeneratieve ziekten. Tijdschr Neurol Neurochir. 2007;108:115–20.
45.
Pijnenburg Y, Jansma K, Tol M van, et al. Frontotemporale dementie: best practice – diagnostiek en management. Amsterdam: FTD-Expertgroep; 2012. www.​ftdexpertgroep.​nl.
46.
Bouma, A. et al. Handboek neuropsychologische diagnostiek. Amsterdam: Pearson; 2012.
47.
Lezak M. Neuropsychological Assessment. 5th edition. New York: Oxford Un Pr; 2012.
48.
Bloem BA, Laar T van, Keus SHJ, et al. Multidisciplinaire richtlijn – ziekte van Parkinson. Alphen aan de Rijn: van Zuiden Communications B.V; 2010.
49.
50.
Spielberger S, Poewe W. Overview of parkinsonism and approach to differential diagnosis. In: Burn D, redactie. Oxford textbook of movement disorders. Oxford: Oxford University Press; 2013; pag. 61–72.CrossRef
51.
Morgan JC, Mehta SH, Sethi KD. Differential diagnosis. In: Pahwa R, Lyons KE, redactie. Handbook of Parkinson’s disease. Boca Raton, London, New York: CRC Press; 2013.CrossRef
52.
Defazio G, Tinazzi M, Berardelli A. How pain arises in Parkinson’s disease? Eur J Neurol. 2013;20(12):1517–23.PubMedCrossRef
53.
54.
Iranzo A, Fernández-Arcos A, Tolosa E, et al. Neurodegenerative disorder risk in idiopathic REM Sleep Behavior Disorder: study in 174 patients. PLoS One. 2014;9/2:e89741.PubMedPubMedCentralCrossRef
55.
Postuma RB, Gagnon JF, Vendette M. Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology. 2009;72(15):1296–300.PubMedPubMedCentralCrossRef
56.
Chaudhuri KR, Pal S, DiMarco A, et al. The Parkinson’s disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2002;73:629–35.CrossRef
57.
Weerkamp NJ, Tissingh G, Poels PJ, et al. Nonmotor symptoms in nursing home residents with Parkinson’s disease: prevalence and effect on quality of life. J Am Geriatr Soc. 2013;61/10:1714–21.PubMedCrossRef
58.
Mack J, Rabins P, Anderson K, et al. Prevalence of psychotic symptoms in a community-based Parkinson’s disease sample. Am J Geriatr Psychiatry. 2012;20/2:123–32.PubMedPubMedCentralCrossRef
59.
Yoritaka A, Shimo Y, Takanashi M, et al. Motor and non-motor symptoms of 1453 patients with Parkinson’s disease: Prevalence and risks. Parkinsonism Relat Disord. 2013;19/8:731–5.
60.
Voss T, Bahr D, Cummings J, et al. Performance of a shortened scale for assessment of positive symptoms for Parkinson’s disease psychosis. Parkinsonism Relat Disord. 2013;19/3:295–9.CrossRef
61.
Boorsma M, Joling KJ, Frijters DHM, et al. The prevalence, incidence and risk factors for delirium in Dutch nursing homes and residential care homes. Int J Geriatr Psychiatry. 2012;27/7:709–15.PubMedCrossRef
62.
Schuurmans MJ, Shortridge-Baggett LM, Duursma SA. The delirium observation screening scale: a screening instrument for delirium. Res Theory Nurs Pract. 2003;17(1):31–50.PubMedCrossRef
63.
Inouye SK, Dyck CH van, Alessi CA, Balkin S, Siegal AP, Horwitz RI. Clarifying confusion: the confusion assessment method. A new method for detection of delirium. Ann Intern Med. 1990 Dec 15;113(12):941–8.PubMedCrossRef
64.
NVKG. Richtlijn delier volwassenen en ouderen. Utrecht: Nederlandse Vereniging voor Klinische Geriatrie; 2013. www.​nvkg.​nl.
65.
Yarnall AJ, Breen DP, Duncan GW, et al. Characterizing mild cognitive impairment in incident Parkinson disease: the ICICLE-PD study. Neurology. 2014 Jan 28;82(4):308–16.PubMedCrossRef
66.
67.
Aarsland A, Hutchinson M, Larsen JP. Cognitive, psychiatric and motor response to galantamine in Parkinson’s disease with dementia. Int J Geriatr Psychiatry. 2003;18:937–41.PubMedCrossRef
68.
Buter TC, Hout A van den, Matthews FE, et al. Dementia and survival in Parkinson disease: a 12-year population study. Neurology 2008(70/13):1017–22.PubMedCrossRef
69.
Hely MA, Reid WG, Adena MA, et al. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord. 2008;(23/6):837–44.PubMedCrossRef
70.
Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease. A clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55/3:181–4.CrossRef
71.
Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord. 2007 Sep 15;22(12):1689–707.PubMedCrossRef
72.
Dubois B, Burn D, Goetz C, et al. Diagnostic procedures for Parkinson’s disease dementia: recommendations from the movement disorder society task force. Mov Disord. 2007;22(16):2314–24.PubMedCrossRef
73.
McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies – Fourth consensus report of the DLB Consortium. Neurology 2017;89:88–100.
74.
Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol. 1964;10:333–59.PubMedCrossRef
75.
Litvan I, Agid Y, Calne D, et al.Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996;47(1):1–9.PubMedCrossRef
76.
Williams DR, Silva R de, Paviuor DC. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson’s syndrome and PSP-parkinsonism. Brain 2005;128:1247–58.PubMedCrossRef
77.
Höglinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord. 2017;32(6):853–64.
78.
Reitan RM. The relation of the trail making test to organic brain damage. J Consult Psychol. 1955;19(5):393–4.PubMedCrossRef
79.
Stroop J. Studies of interference in serial verbal reaction. J Experiment Psychol. 1935;18:643–62.CrossRef
80.
81.
Luzzi S, Fabi K, Pesallaccia M, et al. Applause sign: is it really specific for Parkinsonian disorders? Evidence from cortical dementias. J Neurol Neurosurg Psychiatry. 2011;82(8):830–3.CrossRef
82.
Wu LJ, Sitburana O, Davidson A, et al. Applause sign in Parkinsonian disorders and Huntington’s disease. Mov Disord. 2008;23(16):2307–11.PubMedCrossRef
83.
Schmand B, Groenink SC, Dungen vd M. Letterfluency: psychometrische eigenschappen en Nederlandse normen. Tijdschr Gerontol Geriatr. 2008;39/2:65–77.
84.
Mattis S. Dementia rating scale; professional manual. Odessa, Fl: Psychological Assessment Resources Inc.; 1988.
85.
Krishnan S, Mathuranath PS, Sarma S, et al. Neuropsychological functions in progressive supranuclear palsy, multiple system atrophy and Parkinson’s disease. Neurol India 2006;54/3:268–72.
86.
Stamelou M, Diehl-Schmid J, Hapfelmeier A, et al. The frontal assessment battery is not useful to discriminate progressive supranuclear palsy from frontotemporal dementias. Parkinsonism Relat Disord. 2015;21/10:1264–8.CrossRef
87.
88.
Masellis M. Corticobasal syndrome: clinical, neuropsychological, imaging, genetic and pathological features. PhD thesis. Toronto: University of Toronto; 2012.
89.
Riley DE, Lang AE, Lewis A, et al. Cortical-basal ganglionic degeneration. Neurology 1990;40:1203–12.PubMedCrossRef
90.
Rana AQ, Ansari H, Siddiqui I. The relationship between arm dystonia in corticobasal degeneration and handedness. J Clin Neurosci. 2012;19:1134–6.PubMedCrossRef
91.
Pillon B, Blin J, Vidailhet M, et al. The neuropsychological pattern of corticobasal degeneration: comparison with progressive supranuclear palsy and Alzheimer’s disease. Neurology 1995;45:1477–83.PubMedCrossRef
92.
Dickson DW, Bergeron C, Chin SS, et al. Office of rare diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol. 2002;61/11:935–46.CrossRef
93.
Bürger K, Arzberger T, Stephan J, et al. Pathomechanismen und klinische Aspekte der frontotemporalen Lobärdegeneration. Nervenarzt. 2016;88:163–72.CrossRef
94.
Schrag A, Sheikh S, Quinn NP, et al. A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy. Mov Disord. 2010;25:1077–81.PubMedCrossRef
95.
Siri C, Duerr S, Canesi M, et al. A cross-sectional multicenter study of cognitive and behavioural features in multiple system atrophy patients of the parkinsonian and cerebellar type. J Neural Transm. 2013;120:613–8.PubMedCrossRef
96.
Ceponiene R, Edland SD, Reid TN, et al. Neuropsychiatric symptoms and their impact on quality of life in multiple system atrophy. Cogen Psychol. 2016;3:1–10.
97.
Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008;71/9:670–6.
98.
Brown RG, Lacomblez L, Landwehrmeyer BG, et al. NNIPPS study group. Cognitive impairment in patients with multiple system atrophy and progressive supranuclear palsy. Brain 2010;133(Pt 8):2382–93.PubMedCrossRef
99.
Stankovic I, Krismer F, Jesic A, et al. Cognitive impairment in multiple system atrophy; A position statement by the Neuropsychology Task Force of the MDS multiple system atrophy (MODIMSA) study group. Mov Disord. 2014;29(7):857–67.PubMedPubMedCentralCrossRef
100.
Foster NL, Wilhelmsen K, Sima AA, et al. Frontotemporal dementia and parkinsonism linked to chromosome 17: a consensus conference. Conference participants. Ann Neurol. 1997;41(6):706–15.PubMedCrossRef
101.
102.
Hutton M, Lendon CL, Rizzu P, et al. Association of missense and 5’-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998;393(6686):702–5.
103.
Baker M, Mackenzie IR, Pickering-Brown SM, et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 2006;442(7105):916–9.
104.
105.
Seneci P. Molecular targets in protein misfolding and neurodegenerative disease. Amsterdam: Academic Press/Elsevier; 2015.
106.
Simoes R, Litvan I. Tauopathies. In: Kompolitit K, Verhagen Metman L, redactie. Movement disorders – vol. I. Amsterdam, etc.: Elsevier; 2010. pag. 219–25.CrossRef
107.
Kuzuhara S, Kokubo Y. Amyotrophic lateral sclerosis – parkinsonism – dementia complex in the Kii peninsula of Japan (Muro disease); a review on recent research and new concept.
108.
Kokubo Y. Diagnostic criteria for amyotrophic lateral sclerosis/Parkinsonism-dementia complex in the Kii Peninsula, Japan. Brain Nerve. 2015;67/7:961–67. (Abstract in English).
109.
Perl DP, Hof PR, Steele JC, et al. Neuropathologic studies of a pure dementing syndrome (Marianas dementia) among the inhabitants of Guam, a form of ALS/parkinsonism dementia complex. Brain Pathol. 1994;4:529. Geciteerd in: Larner AJ. Neuropsychological neurology: the neurocognitive impairments of neurological disorders. Cambridge: Cambridge University Press; 2013.
110.
Shindo A, Ueda Y, Kuzuhara S, et al. Neuropsychological study of lateral sclerosis and parkinsonism-dementia complex in Kii pensinsula, Japan. BMC Neurol. 2014;14/151:1–8.
111.
Peng Q, Wu B, Jiang M. Characterization of behavioral, neuropathological, brain metabolic and key molecular changes in zQ175 knock-in mouse model of Huntington’s disease. PLoS One. 2016;11(2):e0148839.PubMedPubMedCentralCrossRef
112.
Quarrell OWJ, Rigby AS, Barron L, et al. Reduced penetrance alleles for Huntington’s disease: a multi‐centre direct observational study. J Med Genet. 2007;44(3):e68.CrossRef
113.
Kay C, Collins JA, Miedzybrozdka Z, et al. Huntington disease reduced penetrance alleles occur at high frequency in the general population. Neurology 2016;87(3):282–8.PubMedPubMedCentralCrossRef
114.
Estrada-Sanchez AM, Rebec GV. Role of cerebral cortex in the neuropathology of Huntington’s disease. Front Neural Circuits. 2013;7(19):1–9.
115.
VSOP (Vereniging Samenwerkende Ouder- en Patiëntenorganisaties), VvH (Vereniging van Huntington), NHG (Nederlands Huisartsen Genootschap). Informatie voor de huisarts over de ziekte van Huntington. Soest:VSOP; 2010.
116.
Arts NJM, Naarding P. Neuropsychiatrische aspecten van de ziekte van Huntington. Patient Care (Neuropsychiatr Gedragsneurolog). 2005;32(aug):157–65.
117.
Herben-Dekker M, Jurgens C, Middelkoop H. De ziekte van Huntington. In: Kessels R, Eling P, Ponds R, et al. Klinische neuropsychologie. Amsterdam: Boom; 2012. pag. 473–84.
118.
Aziz NA, Burg JM van der, Landwehrmeyer GB. Weight loss in Huntington disease increases with higher CAG repeat number. Neurology 2008;4(71/19):1506–13.
119.
Huntington Study Group. The unified Huntington’s disease rating scale: reliability and consistency. Mov Disord. 1996;11:136–42.
120.
Bylsma FW, Rothlind J, Hall MR, et al. Assessment of adaptive functioning in huntington’s disease. Mov Disord. 1993;8/2:183–90.PubMedCrossRef
121.
Kingma EM, Duijn E van, Timman R, et al. Behavioural problems in Huntington’s disease using the problem behaviours assessment. Gen Hosp Psychiatry. 2008;30:155–61.PubMedCrossRef
122.
Podbielska M, Banik NL, Kurowska E, et al. Myelin recovery in multiple sclerosis: the challenge of remyelination. Brain Sci. 2013 Aug 28;3(3):1282–324.PubMedPubMedCentralCrossRef
123.
Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis, the 2013 revisions. Neurology 2014;83/3:278–86.
124.
125.
Miller D, Barkhof F, Montalban X, et al. Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol. 2015;4(5):281–8.PubMedCrossRef
126.
Tintoré M, Rovira A, Río J, et al. Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis? Neurology 2008;25/70:1079–83.PubMedCrossRef
127.
128.
Milo R, Kahana E. Multiple sclerosis: geoepidemiology, genetics and the environment. Autoimmun Rev. 2010;9(5):A387–94.PubMedCrossRef
129.
Popescu BFGh, Pirko I, Lucchinettie CF, et al. Pathology of multiple sclerosis: where do we stand? Continuum (Minneap Minn). 2013;19/4:901–21.PubMedPubMedCentral
130.
Pender MP. CD8+T-cell Deficiency, Epstein-Barr virus infection, vitamin D deficiency and steps to autoimmunity: a unifying hypothesis. Autoimmune Dis. 2012;Article ID 189096:1–12.CrossRef
131.
Cook SD. Handbook of multiple sclerosis. New York/Basel: Marcel Dekker; 2005.
132.
Kroon J de, Groot V de. Richtlijn multiple sclerose. Ned Tijschr Revalidatiegeneeskd. 2014;6:300–2.
133.
Gross HJ, Watson C. Characteristics, burden of illness, and physical functioning of patients with relapsing-remitting and secondary progressive multiple sclerosis: a cross-sectional US survey. Neuropsychiatr Dis Treat. 2017;13:1349–57.PubMedPubMedCentralCrossRef
134.
135.
Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69/2:292–302.PubMedPubMedCentralCrossRef
136.
Algahtani H, Shirah B. Alassiri A. Tumefactive demyelinating lesions: A comprehensive review. Mult Scler Relat Disord. 2017;14:72–9.PubMedCrossRef
137.
Rao SM, Cognitive function study group. A manual for the brief repeatable battery of neuropsychological tests in multiple sclerosis. New York: National Multiple Sclerosis Society; 1990.
138.
Benedict R, Cookfair D, Gavett R, et al. Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). J Int Neuropsychol Soc. 2006;12:549–58.
139.
Schmahmann JD. An emerging concept: the cerebellar contribution to higher function. Archiv Neurol. 1991;48:1178–87.CrossRef
140.
Schmahmann JD. Disorders of the cerebellum: ataxia, dysmetria of thought, and the cerebellar cognitive affective syndrome. J Neuropsychiatr Clin Neurosci. 2004;16:367–78.CrossRef
141.
Buckner RL. The cerebellum and cognitive function: 25 years of insight from anatomy and neuroimaging. Neuron. 2013;80(3):807–15.PubMedCrossRef
142.
Keage HAD, Carare RO, Friedland RP, et al. Population studies of sporadic cerebral amyloid angiopathy and dementia: a systematic review. BMC Neurol. 2009;9(3):1–8.
143.
144.
Mehndiratta P, Manjila S, Ostergard T, et al. Cerebral amyloid angiopathy-associated intracerebral hemorrhage: pathology and management. Neurosurg Focus. 2012;32(4):E7.
145.
Ellis RJ, Olichney JM, Thal LJ, et al. Cerebral amyloid angiopathy in the brains of patient’s with Alzheimer’s disease: the CERAD experience Part XV. Neurology 1996;46(6):1592–6.PubMedCrossRef
146.
Fernandez-Madrid I, Levy E, Marder K, Frangione B. Codon 618 variant of Alzheimer amyloid gene associated with inherited cerebral hemorrhage. Ann Neurol. 1991;30:730–3.PubMedCrossRef
147.
Panegyres PK, Kwok JB, Schofield PR, et al. A Western Australian kindred with Dutch cerebral amyloid angiopathy. J Neurol Sci. 2005;239(1):75–80.PubMedCrossRef
148.
Bornebroek M, Westendorp RGJ, Haan J, et al. Mortality from hereditary cerebral haemorrhage with amyloidosis—Dutch type. The impact of sex, parental transmission and year of birth. Brain 1997;120:2243–9.PubMedCrossRef
149.
Etten ES van, Gurol ME, Grond J van der, et al. Recurrent hemorrhage risk and mortality in hereditary and sporadic cerebral amyloid angiopathy. Neurology 2016;87:1482–7.PubMedPubMedCentralCrossRef
150.
Wattendorf AR, Frangione B, Luyendijk W, et al. Hereditary cerebral haemorrhage with amyloidosis, Dutch type (HCHWA-D): clinicopathological studies. J Neurol Neurosurg Psychiatry. 1995;58:699–705.
151.
152.
153.
154.
Matthews FE, Brayne C, Lowe J, et al. Epidemiological pathology of dementia: attributable risks at death in the medical research council cognitive function and ageing study. Plos Med. 2009;6(11)/e1000180:1–15.PubMedPubMedCentralCrossRef
155.
Bornebroek M, Haan J, Bakker E, et al. Clinical and genetic aspects of hereditary cerebral hemorrhage with amyloidosis-Dutch type (HCHWA-D). In: Verbeek MM, Waal RM de, Vinters HV, redactie. Cerebral amyloid angiopathy in alzheimer’s disease and related disorders. Dordrecht: Springer Science and Business Media BV; 2000. pag. 103–119.
156.
Haan J, Lanser JB, Zijderveld I, et al. Dementia in hereditary cerebral hemorrhage with amyloidosis-Dutch type. Arch Neurol. 1990;47(9):965–7.PubMedCrossRef
157.
WHO. World health Organisation. Internationale statistische classificatie van ziekten en met gezondheid verband houdende problemen – 10e revisie. (ICD-10). Genève: WHO; 1999.
158.
159.
160.
Berg L van den, Berg JP van den, Goeijen JC de, et al. Amyotrofe lateraalsclerose – Landelijke richtlijn 2.0. Utrecht: Integraal Kankercentrum Nederland; 2010.
161.
Zarei S, Carr K, Reiley L, et al. A comprehensive review of amyotrophic lateral sclerosis. Surg Neurol Int. 2015;6/171:1–23.
162.
Longinetti E, Mariosa D, Larsson H, et al. Neurodegenerative and psychiatric diseases among families with amyotrophic lateral sclerosis. Neurology 2017;89(6):578–85.PubMedPubMedCentralCrossRef
163.
Phukan J, Pender NP, Hardiman O. Cognitive impairment in amyotrophic lateral sclerosis. Lancet Neurol. 2007;6(11):994–1003.PubMedCrossRef
164.
Strong MJ, Grace GM, Freedman M, et al. Consensus criteria for the diagnosis of frontotemporal cognitive and behavioural syndromes in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2009;10(3):131–46.PubMedCrossRef
165.
Strong MJ, Abrahams S, Goldstein LH, et al. Amyotrophic lateral sclerosis – frontotemporal spectrum disorder (ALS-FTSD): revised diagnostic criteria. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(3–4):153–74.PubMedCrossRef
166.
Brooks BR, Miller RG, Swash M, et al., for the World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. ALS Other Motor Neuron disord. 2000;1:293–9.
167.
Schelhaas J, Veldink J. Diagnostiek en differntiaal diagnose. In: Berg L van den, Creemers H, Goeijen N de, et al. Zakboekje ALS – amyotrofe lateraal sclerose. Diagnostiek en behandeling – 5 jaar ALS centrum. Utrecht: ALS Centrum Nederland – UMC Utrecht; 2013.
168.
Abrahams S, Newton J, Niven E, et al. Screening for cognition and behaviour changes in ALS. Amyotrop Lateral Scler Frontotemporal Degener. 2014;15:9–14.PubMedCrossRef
169.
Creemers H, Morée S de, Veldink JH, et al. Factors related to caregiver strain in ALS: a longitudinal study. J Neurol Neurosurg Psychiatry. 2016;87(7):775–81.CrossRef
Metagegevens
Titel
Neuropsychologische aspecten van neurodegeneratieve aandoeningen
Auteur
Dr. Ben van Cranenburgh
Copyright
2018
Uitgeverij
Bohn Stafleu van Loghum
Boek
Neuropsychologie

Print ISBN: 978-90-368-2073-8

Elektronisch ISBN: 978-90-368-2074-5

Copyright: 2018

DOI
https://doi.org/10.1007/978-90-368-2074-5_17